ALMS

Alumis Inc

• Seeking Alpha·7h ago

  Healthcare stocks with A+ momentum investors are watching

• The Motley Fool·2d ago

  Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

• TipRanks·05/04 11:06

  Wells Fargo Sticks to Their Buy Rating for Alumis Inc. (ALMS)

• PUBT·04/30 20:30

  Cue Biopharma names Shao-Lee Lin CEO, replacing interim chief Lucinda Warren

• TipRanks·04/15 10:15

  Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target

• Simply Wall St·04/09 17:21

  How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile

• Seeking Alpha·04/07 16:03

  Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy

• Simply Wall St·04/06 01:22

  Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans

• TipRanks·04/04 15:00

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• NASDAQ·04/02 15:48

  Commit To Buy Alumis At $15, Earn 34.6% Annualized Using Options

• Simply Wall St·04/02 00:34

  Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans

• Benzinga·03/30 16:54

  Why Is Alumis Stock Falling Monday?

• TipRanks·03/30 16:08

  Alumis falls -16.1%

• TipRanks·03/30 15:55

  Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS

• TipRanks·03/30 15:50

  Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James